DLL4 and cancer: Hu and colleagues have found that combining Dll4-targeted siRNA with VEGF inhibition bevacizumab was more effective in inhibiting angiogenesis in preclinical models of cancer, and patients with tumors after treatment with anti-VEGF therapy had lower Dll4 expression [36].